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Abstract
BACKGROUND—Robust comparisons of population-based cancer survival estimates require 
tight adherence to the study protocol, standardized quality control, appropriate life tables of 
background mortality, and centralized analysis. The CONCORD program established worldwide 
surveillance of population-based cancer survival in 2015, analyzing individual data on 26 million 
patients (including 10 million US patients) diagnosed between 1995 and 2009 with 1 of 10 
common malignancies.
METHODS—In this Cancer supplement, we analyzed data from 37 state cancer registries that 
participated in the second cycle of the CONCORD program (CONCORD-2), covering 
approximately 80% of the US population. Data quality checks were performed in 3 consecutive 
phases: protocol adherence, exclusions, and editorial checks. One-, 3-, and 5-year age-
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standardized net survival was estimated using the Pohar Perme estimator and state- and race-
specific life tables of all-cause mortality for each year. The cohort approach was adopted for 
patients diagnosed between 2001 and 2003, and the complete approach for patients diagnosed 
between 2004 and 2009.
RESULTS—Articles in this supplement report population coverage, data quality indicators, and 
age-standardized 5-year net survival by state, race, and stage at diagnosis. Examples of tables, bar 
charts, and funnel plots are provided in this article.
CONCLUSIONS—Population-based cancer survival is a key measure of the overall effectiveness 
of services in providing equitable health care. The high quality of US cancer registry data, 80% 
population coverage, and use of an unbiased net survival estimator ensure that the survival trends 
reported in this supplement are robustly comparable by race and state. The results can be used by 
policymakers to identify and address inequities in cancer survival in each state and for the United 
States nationally.
Keywords
cancer; National Program for Cancer Registries (NPCR); population-based survival; statistical 
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INTRODUCTION
Population-based cancer survival is a measure of the overall effectiveness of the health 
system in dealing with cancer.1 Comparisons of population-based cancer survival require 
adherence to a well-designed protocol, standardized quality control procedures, appropriate 
life tables of background mortality, and centralized analysis with the latest statistical 
methods.2,3
The second cycle of the CONCORD program (CONCORD-2) established worldwide 
surveillance of cancer survival in 2015, with estimates of 5-year net survival based on 
individual data for more than 25 million cancer patients (approximately 10 million patients 
in the United States) diagnosed between 1995 and 2009 with 1 of 10 common cancers: 
stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, prostate, and leukemia in 
adults (15–99 years old) and acute lymphoblastic leukemia in children (0–14 years old).3 
Patients were followed up to December 31, 2009.
For the articles in this Cancer supplement, we analyzed data from 37 statewide cancer 
registries (27 funded by the National Program for Cancer Registries [NPCR] program, 5 
funded by the Surveillance, Epidemiology, and End Results [SEER] program, and 5 funded 
by both NPCR and SEER) that participated in CONCORD-2. These registries, which cover 
approximately 80% of the US population, agreed to the inclusion of their data in more 
detailed analyses by stage at diagnosis and by race (Fig. 1). The CONCORD protocol 
required data on stage only for patients diagnosed from January 1, 2001 onward; these 
analyses, focusing mainly on survival by race and stage at diagnosis, were restricted to 
patients diagnosed between 2001 and 2009.
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Public health surveillance using data from population-based cancer registries is a key 
component of cancer control.4 The North American Association of Central Cancer 
Registries (NAACCR) develops and promotes uniform data standards for all cancer 
registries in North America.5 Participating US registries had to meet the NAACCR 
certification criteria and to have conducted record linkage with both state vital records and 
the National Death Index to update the vital status of registered patients. NAACCR members 
developed a detailed SAS program to map the NAACCR database record structure to the 
CONCORD protocol and thus to enable all North American registries to exclude cases that 
would not have been considered reportable primaries according to the International 
Association of Cancer Registries’ (IACR) multiple primary rules,6 before their data sets for 
1995–2009 were extracted for CONCORD-2. This was necessary because North American 
registries define multiple primary cancers under the rules of the SEER program,7 whereas 
registries in the European Network of Cancer Registries and in other continents generally 
use the rules of the IACR, which are more conservative.
Topography and morphology were coded according to the International Classification of 
Diseases for Oncology, Third Edition (ICD-O-3).8 Solid tumors were defined by anatomical 
site (Table 1). For ovarian cancer, we included the fallopian tube, uterine ligaments, and 
adnexa as well as the peritoneum and retroperitoneum, where high-grade serous ovarian 
carcinomas are often detected; this was done to improve the international comparability of 
the data sets. Kaposi’s sarcoma and solid tumors with a lymphoma morphology were 
excluded from analysis.
Leukemias were defined by morphology. In this supplement, we cover only precursor-cell 
acute lymphoblastic leukemia in children (ICD-O-3 morphology codes 9727, 9728, 9729, 
9835, 9836, and 9837). Estimates of survival by race, state, and subtype of adult leukemia 
will be presented in other publications.
Only primary invasive cancers (ICD-O-3 behavior code 3) were included in survival 
analyses. We included cancers at a given site regardless of whether the patient had had a 
previous cancer. If a patient had been diagnosed with 2 or more cancers of a given organ, 
including paired organs, between 2001 and 2009, only the first was considered in survival 
analyses.
FOLLOW-UP
US registries were asked to submit follow-up data (the vital status and the date of the last 
known vital status) as of December 31, 2009, after conducting linkages of all cancer 
registrations with both state vital records systems and the National Death Index. Patients 
whose cancer registration could not be linked to a death record were considered to be alive 
on December 31, 2009 (passive follow-up, which is also known as the “presumed alive” 
method).
SEER registries are required to meet a specific standard for the completeness and recency of 
follow-up. At least 90% of registered patients not known to be deceased were required to 
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have a date of last known vital status on or after January 1, 2010. These follow-up dates 
could have been obtained from either passive or active follow-up.9
Patients whose survival time was unknown were excluded from analyses. This group 
comprised patients registered solely from a death certificate or diagnosed at autopsy.
DATA QUALITY CONTROL
We performed data quality checks in 3 consecutive phases: protocol adherence, exclusions, 
and editorial checks. After each phase, a detailed report was sent to each cancer registry.
Phase 1: Protocol Adherence
We first checked the compliance with the CONCORD-2 protocol of each of 37 variables 
(demographic characteristics, basis of diagnosis, date of diagnosis, topography, morphology, 
behavior, stage, vital status, and date of last known vital status) in each tumor record in each 
data set. Any value not specified in the protocol was considered noncompliant. Each registry 
was sent a table of the number of records and the percentage compliance for each variable 
and for each cancer. Minor issues were corrected by the CONCORD Central Analytic Team 
after discussion with the registry. For major structural issues, 5 registries corrected and 
resubmitted their data.
Phase 2: Exclusions
Next, we checked for logical inconsistencies between the variables in each tumor record, for 
each cancer site. Exclusion criteria were defined a priori on the basis of the experience 
within the Cancer Survival Group, the checks performed in the first CONCORD study, the 
data quality checks of EURO-CARE (a European cancer registry–based study of the survival 
and care of cancer patients), the checks proposed by the International Agency for Research 
on Cancer, the descriptions of morphology in the World Health Organization/International 
Agency for Research on Cancer classification of tumors for each cancer, and, finally, clinical 
expertise.3
We produced exclusion tables summarizing the quality of each data set. Data quality 
indicators were tabulated separately for patients diagnosed in 1995–1999, 2000–2004, and 
2005–2009 to enable evaluations of trends in data quality over time. We defined 3 broad 
categories for exclusion: ineligibility (eg, an in situ neoplasm), definite error (eg, a sex-site 
mismatch), and possible error (eg, an apparent inconsistency between site and morphology). 
We had requested records of in situ neoplasms to assess the intensity of diagnostic activity, 
particularly for cancers of the breast and cervix, but in situ neoplasms were not included in 
survival analyses. The number and percentage of patients excluded from analyses are shown 
in Table 2.
The majority of the patients (99.6%) had only a single tumor record for any 1 cancer 
between 1995 and 2009. However, since a small proportion of patients had more than 1 
tumor record for a given cancer (“multiple tumor, same site”), it was necessary to apply the 
quality control checks to every tumor record independently before we selected the single 
tumor record to be included in survival analyses. For example, if a woman had an in situ 
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neoplasm of the breast diagnosed in 2001 followed by an invasive primary breast cancer in 
2007, the invasive cancer record was selected for inclusion in the analyses as long as it was 
free of error.
Phase 3: Editorial Tables
We evaluated the distribution of key data quality indicators for each cancer and for each 
registry. These indicators included the proportion of cancers in the final data set that had 
been microscopically verified and the proportion of patients who had been lost to follow-up. 
We also checked the distributions of the day and the month of the dates of birth, diagnosis, 
and last known vital status. These distributions should be flat because one would expect 
approximately 8% of births, diagnoses, and deaths to occur in each month, and 
approximately 3% to occur on each day of a given month, except for days 29 to 31: spikes in 
these distributions, often on the 1st, 15th, or 16th day of the month, or in June or July, 
helped to identify where registries had imputed missing elements of each date.
Table 2 provides a summary of the exclusions and data quality indicators for adults (15–99 
years) diagnosed between 1995 and 2009 with 1 of 9 common cancers (all solid cancers), by 
US state. The calendar periods within which survival analyses could be performed by stage 
at diagnosis were constrained by the availability of data on stage only from 2001 onward, 
and by the change in coding from 2004 (discussed later). Therefore, the periods for which 
data quality indicators are presented do not exactly match the periods used for survival 
analysis. However, data quality has generally been very high in all US registries, and it 
tended to improve over the 15 years from 1995 to 2009. Only about 2% of tumors were 
registered from a death certificate only (DCO) or detected solely at autopsy. These records 
must be excluded from survival analyses because the follow-up time for these patients is 
unknown. However, the proportion of DCO registrations in the United States was low 
overall (1.9%) and in all states (range <0.1% to 3.5%). The proportion of other errors was 
very low (0.2%). Therefore, approximately 98% of eligible patients were included in 
survival analyses. Practically all tumors (99.7%) were microscopically verified: this 
proportion was more than 95% in almost all US states.
The proportion of the US population covered by this study is 80.6%. Table 3 shows the 
population coverage by US state, as well as the number of patients diagnosed between 1995 
and 2009 and included in the analyses.
STUDY DESIGN
The focus of this monograph is the striking differences in survival by race and stage at 
diagnosis. Because differences in survival between men and women were generally very 
small compared to the differences in survival between blacks and whites (Table 4), we do 
not show survival estimates by sex in the articles on each cancer.
The CONCORD protocol required information on the stage at diagnosis only for patients 
diagnosed from 2001 onward, because the completeness of data on stage in the United States 
and many other countries was known to be much lower before 2001. For the analyses of 
survival by stage at diagnosis, patients were grouped by year of diagnosis into 2 calendar 
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periods (2001–2003 and 2004–2009) to reflect changes in the methods used by US registries 
to collect data on the stage at diagnosis. From 2001 onward, most registries coded stage 
directly from the source data to SEER Summary Stage 2000.10 From 2004 onward, all 
registries began to derive SEER Summary Stage 2000 from 15 pathological and clinical data 
items, using the Collaborative Staging System.11 Data on stage at diagnosis were not 
available for Maryland or Wisconsin, or for patients diagnosed between 2004 and 2009 in 
Rhode Island.
We estimated net survival with the cohort approach for patients diagnosed in 2001–2003 
because all patients had been followed up for at least 5 years by December 31, 2009. We 
used the complete approach to estimate net survival for patients diagnosed from 2004 to 
2009 because 5 years of follow-up data were not available for all patients.
Cohort Approach
The cohort approach is the classic approach to survival analysis: all patients who are 
included in the analysis have had the opportunity to be followed for the full duration of the 
survival analysis (in this case, 5 years). The cohort of patients is defined by the year or 
calendar period during which they were diagnosed, and each patient is followed for the same 
length of time. In our analyses, at least 5 years of follow-up for vital status were available by 
the end of 2009 for all patients diagnosed between 2001 and 2003. Each patient, regardless 
of his or her actual year of diagnosis, contributes survival information at each point in 
follow-up time that, taken cumulatively, make up the survival estimate at 5 years.
The cohort approach is considered the gold standard12,13 because it provides a survival 
estimate for a group of patients who have been diagnosed during the same year or period, 
who are likely to have been treated in a similar fashion, and who have all been followed for 
at least the duration of survival required. It is the natural approach to estimation of the 
outcome and is easy to interpret, but other approaches may be required if sufficient data are 
not available.
Complete Approach
The complete approach can be applied to estimate survival for patients who have been 
diagnosed more recently, and for whom 5 full years of follow-up data may not be available 
at the closing date of the study. For example, some patients diagnosed in 2004–2009 were 
followed for less than 5 years. The cohort approach can be used to estimate 5-year survival 
for patients diagnosed in 2004, but 5-year survival can be estimated for the whole calendar 
period with the complete approach, in which all the available follow-up data for patients 
diagnosed between 2004 and 2009 are used. The potential follow-up time for these patients 
varies between 1 and 5 years.
Age Standardization
We compared survival estimates between US states, between blacks and whites, and between 
calendar periods of diagnosis. For age-specific survival estimates, a comparison between 
populations or over time is straightforward, but if we want to compare overall (all-ages) 
survival estimates, age standardization is required. This is essentially for the same reasons as 
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in comparison of overall incidence or mortality rates, namely that net survival may also vary 
widely with age at diagnosis, and the age profile of cancer patients may differ between the 
populations or change between the calendar periods among which we wish to compare 
overall survival.
For age standardization of incidence or mortality rates, what matters is the age structure of 
the general population at risk of cancer. With cancer survival, however, what matters is the 
age profile of cancer patients, which is very different from the age profile of the general 
population. The weights used for age standardization of cancer survival estimates are thus 
completely different from those required for standardizing incidence or mortality rates. The 
weight for each age group is provided by the proportion of cancer patients in that age group 
in a standard population of cancer patients.
The International Cancer Survival Standard weights (ICSS)14 are strongly recommended for 
international comparisons of cancer survival. They comprise 3 sets of standard age weights, 
derived from discriminant analysis to find the smallest number of sets of weights that enable 
adequate standardization of survival. Each standard is applicable to a range of different 
cancers, and provides age-standardized survival estimates that are not too different from the 
unstandardized estimates. The same age weights can be used for men and women, and for 
direct comparisons of age-standardized net survival between patient groups defined by sex 
and race.
STATISTICAL METHODS
We estimated net survival up to 5 years after diagnosis with 95% confidence intervals (CI), 
using the Pohar Perme estimator, implemented in the Stata algorithm.15–17 We analyzed 
survival by state, race, stage at diagnosis, and calendar period of diagnosis. Net survival is 
the probability of surviving up to a given time since diagnosis after controlling for other 
causes of death (background mortality). To control for the wide differences in background 
mortality among participating states and racial/ethnic groups, we constructed life tables of 
all-cause mortality in the general population of each state from the number of deaths and the 
population by single year of age, sex, calendar year, and, where possible, race (black and 
white).
Net survival in adults was estimated for 5 age groups (15–44, 45–54, 55–64, 65–74, and 75–
99 years; except for prostate cancer 15–54, 55–64, 65–74, 75–84 and 85–99 years). We 
obtained age-standardized survival estimates using the International Cancer Survival 
Standard weights. For children, survival was estimated for the age groups 0 to 4, 5 to 9, and 
10 to 14 years. We obtained age-standardized estimates by assigning equal weights to the 3 
age-specific estimates.18
We derived standard errors for both unstandardized and age-standardized survival estimates 
with the Greenwood method,19 assuming a normal distribution, and truncated to the range 
0–100. We did not estimate survival if fewer than 10 patients were available for analysis. 
Age standardization was performed only if there were at least 10 patients in each of the age 
categories specified above. If an age-specific estimate could not be obtained, we merged data 
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for adjacent age groups and assigned the combined estimate to both age groups. If 2 or more 
age-specific estimates could not be obtained, we present only the pooled, unstandardized 
estimates for all ages combined: these estimates are italicized in Supporting Tables 2 and 3 
in other articles of this supplement.20–29
For each of the 37 states, we present estimates of age-standardized net survival for each 
cancer up to 5 years after diagnosis. For convenience, we report cumulative survival 
probabilities (range, 0–1) as percentages in the range of 0% to 100%.
LIFE TABLES
For the analyses presented in this supplement, we used the life tables for background 
mortality that were constructed for the CONCORD-2 study.30
To control for variation between US states in background mortality by age, sex, race, and 
calendar year while estimating net survival, we used life tables of all-cause mortality rates 
by single year of age (0–99 years) for each state, race, calendar year (2001–2010), and sex. 
For a few states in which the black population is small, it was not possible to construct 
adequately robust life tables of all-cause mortality by single year of age and sex for blacks, 
so net survival estimates for blacks in those states are not presented separately. These life 
tables can be downloaded from the CONCORD library of over 12,000 life tables.31 The 
library includes detailed statistical and graphical reports on the robustness of the life tables 
for each US state.
We received raw data on death counts and populations for each US state. To produce life 
tables for each US state by race, sex, and calendar year (state- and race-specific life tables), 
we used a flexible Poisson model32 that enables creation of single-year-of-age life tables 
even when the raw data are sparse. We checked the life tables by examination of semilog 
plots of the age-sex-mortality rates, the life expectancy at birth, the probability of death in 
the age bands 15 to 59, 60 to 84, and 85 to 99 years, and, where necessary, the model 
residuals, to examine the goodness of fit of the models by age and sex.
GRAPHICAL REPRESENTATION
In each cancer-specific article in this supplement, trends, geographic variations, and 
differences in age-standardized survival by race are presented graphically in bar charts and 
funnel plots.33
Bar Charts
Results are summarized in bar charts of 5-year age-standardized net survival by calendar 
period (2001–2003 and 2004–2009), for each state, grouped within the 4 US Census 
geographic regions (Northeast, South, Midwest, and West). The results for each region are 
presented with a different color. Within each region, darker shades indicate NPCR registries, 
whereas lighter shades indicate SEER registries. Five registries funded by both SEER and 
NPCR were grouped with SEER because they use both passive and active follow-up; they 
are indicated with an asterisk.
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The survival estimates for each state in 2004–2009 are ranked from high to low within each 
US Census region. The same ranking is then applied to the results for 2001–2003, to 
facilitate examination of changes in survival from 2001–2003 to 2004–2009 within each 
state. The absolute difference in 5-year net survival between the 2 periods is also shown for 
each state as a percentage.
Each graphic includes the pooled survival estimates for all 37 participating states combined.
Funnel Plots
Funnel plots are graphical representations designed to detect excessive variation in 
performance indicators by simple visual inspection of the data.34 They provide a simple and 
informative display of geographical variation or time trends in population-based cancer 
survival measures (eg, age-standardized net survival).
A funnel plot comprises 4 elements33: the target (or reference) value for the outcome, a set 
of control limits (the funnel), data points for the outcome variable (indicator), and the 
associated precision parameter for each data point. Data points outside the control limits (the 
funnel) indicate variation in the indicator beyond what would be expected by chance, while 
taking account of precision.34
The funnel plot in Figure 2 shows, as an example, 5-year age-standardized net survival for 
breast cancer in the United States between 2004 and 2009, by race and state. It is 
constructed by plotting the 37 state-specific survival estimates for breast cancer between 
2004 and 2009 (on the y-axis), against their associated precision (on the x-axis), forming a 
scatter plot. Fewer data points are available for blacks (28 states) than whites (37 states) 
because of the difficulty in constructing robust life tables for blacks in every state. The 
precision parameter in this example is, in fact, the precision of each age-standardized net 
survival estimate (the inverse of its variance). This is a natural choice to represent the 
statistical precision of each estimate, but it could be any function that is proportional to the 
inverse of the variance.
The target (the solid, horizontal line in Fig. 2) is then superimposed. This is a constant value, 
considered independent of the observations, and it specifies the expected value for the 
outcome. The target shown in Figure 2 is the 5-year age-standardized net survival estimate 
for the pooled US data for women diagnosed with breast cancer between 2004 and 2009. 
The pooled US estimate was selected as the target, to show the extent to which survival for 
blacks and whites in each state varies around the overall survival estimate for the United 
States.
The control limits (the dashed lines in Fig. 2) are also independent of the individual survival 
estimates. They depend only on the target value, and their correct formulation depends on 
the underlying theoretical distribution of the target value. The control limits for a given level 
of significance (α) are drawn around the target value across the entire observed range of 
precision of the individual estimates. The most common levels of significance are α = 5% 
and α = 0.2%, so the resulting 95% and 99.8% control limits represent approximately 2 and 
3 standard deviations, respectively, on either side of the target value at each level of 
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precision. An estimate that appears outside the control limits is identified as diverging from 
the target value and is an “out-of-control” estimate; in other words, it is a probable outlier 
that may need to be investigated further.
In Figure 2, as with all the funnel plots reported in this supplement, 5-year age-standardized 
net survival is represented by open circles for white patients and by solid circles for black 
patients. Funnel plots are extremely powerful tools for visual examination of variation in an 
indicator: we can perceive at first glance that 5-year survival in blacks is persistently lower 
than would be expected (the pooled US survival estimate, ie, the target) and that survival for 
blacks is generally lower than survival for whites.
DISCUSSION
This article summarizes the data quality control procedures, analytic methods, and graphical 
presentations that have been deployed for all the data sets reported in this supplement. The 
quality of the population-based data from the 37 participating US cancer registries was 
impressively high (Table 2). More details about the quality indicators for each cancer can be 
found in the online supplementary appendix (http://www.thelancet.com/journals/lancet/
article/PIIS0140-6736(14)62038-9/supplemental) for the CONCORD-2 article.3
For NPCR registries that use only passive follow-up to determine the vital status of 
registered cancer patients (the “presumed alive” method), survival estimates may be inflated 
if the cancer registrations for some patients who have in fact died could not be successfully 
linked to the data from their death certificate. The vital statistics offices in each state have 
reported all death certificate information to the National Death Index since 1979. Passive 
methods of follow-up are known to be efficient because of the completeness and accuracy of 
the National Death Index, which tends to capture 1% to 3% more deaths than if the registry 
can link its data only to the state death index.35 Most of the extra deaths captured in this way 
will be those of patients who migrated to a different state after their cancer diagnosis. 
However, the registries included in these analyses had all matched their data against the 
National Death Index before data submission, so the completeness of vital status 
ascertainment is expected to be extremely high, although it may not capture out-of-country 
deaths.
A major strength of this study is the use of life tables that are specific for each state, each 
race (white, black), and each calendar year, to control for differences and changes in 
background mortality by single year of age, sex, race, state, and single calendar year. This 
approach provided the tightest possible control of background mortality with the available 
data. More specific life tables may be considered in future studies, subject to the availability 
of high-quality data on death and population counts for Hispanics or other major racial or 
ethnic groups.
The CONCORD-2 protocol required registries to provide information on the stage at 
diagnosis for patients diagnosed in 2001 or later. Calendar years of diagnosis were then 
grouped for analyses of survival by stage into 2001–2003 and 2004–2009, to reflect a 
change in the US stage coding system in 2004.
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This choice of calendar periods imposed the following selection of analytic approach. We 
were able to estimate 5-year net survival with the “cohort” approach for patients diagnosed 
in 2001–2003, since all patients had at least 5 years of potential follow-up. However, the 
“period” approach36 that was adopted to estimate 5-year survival for patients diagnosed 
between 2005 and 2009 in the CONCORD-2 study3 could have been used to estimate 5-year 
survival by stage for patients diagnosed between 2004 and 2009 only if stage data had also 
been available for patients diagnosed in 2000. We therefore adopted the “complete” 
approach. In this approach, more information is available for estimating survival in the early 
years of follow-up than for later years. Only patients diagnosed in 2004 had the potential to 
be followed up for 5 years by December 31, 2009; only patients diagnosed between 2004 
and 2005 had the potential to contribute to the conditional survival probabilities between 4 
and 5 years after diagnosis (and so on). This leads to some increased variation around the 5-
year survival estimates for 2004–2009 compared with those for 2001–2003. This is reflected 
in the confidence intervals, and slightly lower precision, seen in the funnel plots for 2004–
2009 in some of the site-specific articles.
This is the most extensive analysis of 5-year population-based cancer survival in the United 
States to date, with survival trends for 10 common cancers in 37 states that include 80% of 
the US population. Here, we have focused on variations in survival by race and stage at 
diagnosis for patients diagnosed between 2001 and 2009.
Population-based cancer survival is a key measure of the overall effectiveness of the health 
system in dealing with cancer. The high quality of the data from the US cancer registries, 
implementation of the most up-to-date and unbiased estimator of net survival, combined 
with the use of state- and race-specific life tables, all help to ensure that these cancer 
survival estimates are robust and comparable. We believe that they can be confidently used 
by policy-makers to identify inequities in cancer survival by race in each state and for the 
United States as a whole, and to plan cancer control strategies that promote equal 
opportunity for the best possible outcomes after a cancer diagnosis.
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Figure 1. 
Map of the participating states. NPCR indicates National Program for Cancer Registries; 
SEER, Surveillance, Epidemiology, and End Results.
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Figure 2. 
Five-year age-standardized net survival for women (15–99 years old) who were diagnosed 
with breast cancer in 2004–2009, by state and race. Each data point represents the survival 
estimate for a US state for either blacks (28 states) or whites (37 states; see text).
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TABLE 1
Definition of Malignancies
Malignancy Topography or Morphology Codes Description
Stomach C16.0-C16.6, C16.8-C16.9 Stomach
Colon C18.0-C18.9, C19.9 Colon and rectosigmoid junction
Rectum C20.9, C21.0-C21.2, C21.8 Rectum, anus, and anal canal
Liver C22.0-C22.1 Liver and intrahepatic bile ducts
Lung C34.0-C34.3, C34.8-C34.9 Lung and bronchus
Breast (women) C50.0-C50.6, C50.8-C50.9 Breast
Cervix C53.0-C53.1, C53.8-C53.9 Cervix uteri
Ovary C48.0-C48.2, C56.9, C57.0-C57.4, C57.7-C57.9 Ovary, fallopian tube and uterine ligaments, other and unspecified 
female genital organs, peritoneum, and retroperitoneum
Prostate C61.9 Prostate gland
Leukemia (children) 9727, 9728, 9729, 9835, 9836, 9837 Precursor-cell acute lymphoblastic leukemia
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–
–
–
–
−
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.2
C
er
v
ix
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.8
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.2
–6
3.
5
63
.5
62
.7
–6
4.
2
55
.5
53
.9
–5
7.
1
–
–
–
–
−
7.
9
O
va
ry
41
.0
40
.5
–4
1.
5
41
.7
41
.2
–4
2.
2
31
.1
29
.5
–3
2.
7
–
–
–
–
−
10
.6
Pr
o
st
at
e
96
.9
96
.7
–9
7.
1
96
.9
96
.7
–9
7.
1
92
.7
92
.1
–9
3.
3
–
–
–
−
4.
2
–
Le
uk
em
ia
52
.1
51
.7
–5
2.
5
52
.0
51
.5
–5
2.
5
52
.3
51
.7
–5
2.
9
52
.7
52
.3
–5
3.
1
52
.5
51
.9
–5
3.
0
52
.9
52
.3
–5
3.
6
41
.9
40
.4
–4
3.
5
41
.1
38
.9
–4
3.
3
42
.7
40
.6
–4
4.
9
−
0.
3
−
0.
4
−
1.
6
−
11
.3
−
10
.2
A
LL
c
88
.1
87
.2
–8
8.
9
87
.4
86
.2
–8
8.
6
88
.9
87
.6
–9
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2
88
.6
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.6
–8
9.
5
88
.1
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.8
–8
9.
4
89
.1
87
.7
–9
0.
6
83
.6
80
.6
–8
6.
6
82
.3
78
.4
–8
6.
2
85
.1
80
.1
–9
0.
1
−
1.
5
−
1.
0
−
2.
8
−
5.
8
−
4.
0
A
bb
re
v
ia
tio
ns
: A
LL
, a
cu
te
 ly
m
ph
ob
la
sti
c 
le
uk
em
ia
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
; N
S,
 n
et
 su
rv
iv
al
.
Th
e 
po
pu
la
tio
n 
co
v
er
ag
e 
re
pr
es
en
ts 
80
.6
%
 o
f t
he
 U
S 
po
pu
la
tio
n 
in
 2
00
9 
(ac
co
rdi
ng
 to
 th
e U
N 
Po
pu
lat
ion
 D
ivi
sio
n).
a A
 n
eg
at
iv
e 
v
al
ue
 m
ea
ns
 th
at
 m
en
 h
av
e 
lo
w
er
 s
u
rv
iv
al
 th
an
 w
o
m
en
.
b A
 n
eg
at
iv
e 
v
al
ue
 m
ea
ns
 th
at
 b
la
ck
s h
av
e 
lo
w
er
 s
u
rv
iv
al
 th
an
 w
hi
te
s.
c C
hi
ld
re
n 
(0–
14
 ye
ars
 ol
d) 
on
ly.
Cancer. Author manuscript; available in PMC 2018 March 14.
